Asthma Management Across the Lifespan

The purpose of this course is to provide nurses and healthcare professionals with a comprehensive understanding of asthma’s pathophysiology, presentation, diagnostic criteria, and management, addressing a common gap in practice where asthma is frequently underdiagnosed, misclassified, or inadequately controlled. This course equips learners to differentiate asthma from similar conditions, tailor care across age groups, and respond effectively in both outpatient and acute settings.

Asthma is a highly prevalent, chronic inflammatory disease of the airways characterized by variable and reversible airflow obstruction. Asthma presents with symptoms such as wheezing, cough, chest tightness, and shortness of breath that can range from mild to life-threatening. Despite advances in treatment, asthma continues to be underdiagnosed, often poorly controlled, and a significant cause of emergency visits and hospitalizations. Asthma continues to be underdiagnosed, partially because it presents with symptoms that have a broad differential diagnosis, the physical examination may be normal, and the predominant clinical tests may also be normal unless the patient is experiencing an exacerbation (Kavanagh et al., 2019). Asthma is uncontrolled in approximately 50% of children and 62% of adults (Pate & Zahran, 2024).

Understanding asthma requires not only recognition of its hallmark symptoms but also a deeper grasp of its complex pathophysiology, diagnostic challenges, and the interplay of pharmacologic and nonpharmacologic management strategies. This course explores evidence-based practices that enable clinicians to provide safe, effective, and patient-centered care to individuals living with asthma.

Asthma affects millions of people worldwide and represents a major public health concern. Globally, it is estimated that more than 260 million people live with asthma, and the disease contributes significantly to disability-adjusted life years (DALYs) (World Health Organization [WHO], 2024).

In the United States, asthma remains a significant public health concern, with 24.9 million people affected in 2021, about 7.7% of the population (Centers for Disease Control and Prevention [CDC], 2023). Trends over the past two decades show that overall prevalence has increased slightly, rising from 7.4% in 2001 to 7.7% in 2021 (CDC, 2023). Notably, asthma prevalence among adults increased during this period, while the prevalence among children (ages 0 - 17) declined, particularly after 2010. These contrasting trends suggest that while asthma remains common in youth, public health and clinical interventions may be contributing to improved diagnosis and control in pediatric populations, even as adult asthma continues to pose challenges (CDC, 2023).

Risk factors for asthma are multifactorial, including both genetic and environmental factors. A family history of asthma or allergies is a strong predictor, pointing to a hereditary component. Environmental exposures such as allergens (dust mites, pet dander, mold, pollen), air pollutants, secondhand smoke, and respiratory infections during childhood increase risk. Occupational exposures to irritants and chemicals also contribute, especially in adults. Obesity has been identified as both a risk factor and a complicating factor, as it is associated with more severe asthma and reduced responsiveness to standard therapies. Importantly, asthma is characterized by chronic airway inflammation, airway hyperresponsiveness, and intermittent obstruction, though the mechanisms vary across phenotypes (NHLBI, 2024).

Asthma Triggers

(*Please click on the image above to enlarge.)

According to the CDC report, women have a higher prevalence than men, a pattern most pronounced in adulthood. By race and ethnicity, non-Hispanic Black individuals and Puerto Ricans experience disproportionately higher rates of asthma compared to non-Hispanic White and Mexican American populations (CDC, 2023). These demographic disparities highlight the influence of social determinants of health in asthma epidemiology. Low-income populations are disproportionately affected. This may be due to increased exposure to environmental triggers such as poor housing conditions, pests, mold, and indoor air pollutants. Urban communities often experience higher asthma rates, partly due to traffic-related air pollution and limited access to green spaces. Racial and ethnic minorities experience higher prevalence, worse control, and greater hospitalization and mortality rates compared to white populations (CDC, 2023; NHLBI, 2024).

Additionally, access to healthcare, health literacy, housing quality, and environmental changes play critical roles in asthma prevalence and outcomes. Children in households with limited access to consistent medical care are less likely to receive preventive treatments, leading to higher emergency department visits and hospitalizations. Inadequate insurance coverage can also delay diagnosis or limit access to inhaled corticosteroids. Ultimately, while genetics and biology lay the foundation for asthma risk, social and environmental factors shape its epidemiology and outcomes on a population level (NHLBI, 2024).

The pathophysiology of asthma can be described as a two-step process involving both immediate and delayed immune responses following exposure of the airway epithelium to allergens or irritants. When the airway epithelium is exposed to an antigen, the immune system initiates a cascade of events designed to protect the individual, but in asthma, these mechanisms become exaggerated and cause more harm than good. This dysregulated immune response results in airway inflammation, hyperresponsiveness, and remodeling over time.

Presentation of asthma can vary depending on age, severity, and the setting in which symptoms arise, but it typically involves a combination of chronic and acute manifestations.

Acute presentation is characterized by sudden exacerbations or “asthma attacks,” during which symptoms become more severe and may include pronounced wheezing, tachypnea, use of accessory muscles for breathing, or difficulty speaking in full sentences. In severe cases, cyanosis, confusion, or “silent chest” are ominous findings that require immediate intervention (Brashers et al., 2025).

Chronic symptoms often include a persistent or recurrent cough (which may be worse at night or early morning), wheezing, shortness of breath, and chest tightness. These symptoms tend to fluctuate in frequency and intensity, and patients often report that they are triggered by specific exposures such as allergens, respiratory infections, exercise, or changes in weather (Brashers et al., 2025).

In children, asthma may present subtly, especially in its chronic form. Parents often report a recurring cough, particularly at night, after play, or following respiratory infections. Wheezing may be heard intermittently, but in some children, cough is the predominant or only symptom, leading to a diagnosis of “cough variant asthma.” Reports of recurrent episodes of “bronchitis” or “pneumonia” may also suggest undiagnosed asthma. During acute exacerbations, children may present with rapid breathing, retractions, nasal flaring, and difficulty speaking or feeding. Because children may struggle to describe their symptoms, clinicians rely heavily on parental reports of coughing patterns, nighttime awakenings, and response to bronchodilators (Martin et al., 2022).

One useful tool for evaluating asthma in pediatric patients is the Childhood Asthma Control Test (C-ACT), an evidence-based questionnaire designed for children ages 4 to 11. The C-ACT combines the child's self-reported responses (with pictorial response options to aid understanding) and input from the parent or caregiver. Questions focus on the frequency of symptoms such as coughing, wheezing, nighttime awakenings, activity limitations, and the need for rescue inhaler use over the previous four weeks. Each response is scored, and the total score helps determine whether the child’s asthma is well controlled, not well controlled, or poorly controlled. A score of 19 or less generally indicates that asthma is not adequately controlled and may warrant a step-up in therapy, re-evaluation of environmental triggers, or evaluation of treatment adherence. The simplicity and reliability of the C-ACT make it a valuable tool for clinicians, as it provides structured insight into the child’s daily symptom burden and quality of life, supporting both diagnosis and ongoing management (Martin et al., 2022; van Dijk et al., 2020).

In adults, asthma is often easier to recognize by the pattern of wheezing, chest tightness, and variable breathlessness. Adults may describe episodic symptoms that interfere with sleep, physical activity, or work performance. A thorough history should include questions about occupational exposures (e.g., dust, fumes, or chemicals), smoking status, and environmental triggers at home. Adults with asthma often have comorbidities such as allergic rhinitis, gastroesophageal reflux disease (GERD), or obesity, which can complicate presentation and control. Clinicians assessing adults should document the frequency of daytime and nighttime symptoms, the use of rescue inhalers, and any limitations in daily activities, as this information is key to classifying asthma severity and guiding treatment decisions.

Across all age groups, critical assessment data for clinicians include vital signs (respiratory rate, oxygen saturation, heart rate), auscultation findings (wheezing, decreased air entry), and the presence of accessory muscle use, tripod position, or retractions. History-taking should emphasize symptom variability, triggers, family history of asthma or allergies, and response to previous treatments. Identifying patterns such as worsening symptoms at night, improvement after bronchodilator use, or exacerbations linked to allergens provides strong clues toward the diagnosis. Collectively, these clinical observations form the foundation for confirming asthma with objective testing (Brashers et al., 2025).

Asthma is classified based on several key dimensions: severity, control, and phenotype. These categories help guide treatment decisions, predict prognosis, and tailor therapy to the individual patient. Severity reflects the intrinsic intensity of the disease before treatment, while control reflects how well symptoms are managed with current therapy. Phenotyping, a more recent development, categorizes asthma into biologically or clinically distinct subtypes that may respond differently to targeted therapies.

Once asthma has been classified, a multimodal treatment approach is essential to achieve optimal control and prevent long-term complications. This approach integrates pharmacologic therapy with nonpharmacologic interventions and should be individualized for each unique patient. Further discussion of management strategies is below.

Exercise-induced bronchoconstriction (EIB) is a common issue among athletes, affecting 20-70% of athletes across specific sports, and is often referred to as exercise-induced asthma; however, it is distinct from chronic asthma (Ora et al., 2024; UPMC, 2021). As described earlier, chronic asthma can be triggered by a variety of factors, including allergies that trigger the airways in the lungs to become inflamed and narrowed. EIB is a transient narrowing of the airways that occurs during or after physical activity. It is characterized by symptoms such as coughing, wheezing, shortness of breath, and chest tightness, typically peaking 5 to 10 minutes post-exercise (Anderson & Kippelen, 2019). Although EIB can occur in individuals with chronic asthma, it is also observed in otherwise healthy athletes, especially those exposed to cold, dry air or environmental irritants such as chlorine or pollutants (Weiler et al., 2016). EIB is believed to result from heat and water loss from the airways during hyperventilation associated with exercise, leading to airway inflammation and smooth muscle constriction (Morris, 2020).

Management of EIB encompasses both pharmacological and non-pharmacological approaches. Short-acting beta-2 agonists (SABAs), such as albuterol, administered 15–20 minutes before exercise, remain the first-line preventive therapy (Global Initiative for Asthma [GINA], 2024). Long-term control may involve inhaled corticosteroids or leukotriene receptor antagonists for individuals with persistent symptoms (Weiler et al., 2016). Non-pharmacologic strategies include adequate warm-up, nasal breathing when possible, and environmental modifications to reduce exposure to cold or irritants (Anderson & Kippelen, 2019).

Athletic trainers (ATs) must be prepared to care for patients experiencing respiratory emergencies, such as asthma and EIB. Administering a short-acting bronchodilator via a metered-dose inhaler and using a nebulizer are longstanding skills of ATs; in fact, the 2020 Commission on Accreditation of Athletic Training Education (CAATE) curricular standards require AT students to be trained to administer lifesaving medications, including bronchodilators (CAATE, 2020; Hoffman et al, 2021). ATs play a crucial role in identifying, managing, and preventing EIB among athletes. They are often the first to recognize symptoms during activity and should ensure that athletes with known EIB have a current asthma action plan and access to inhalers (National Athletic Trainers’ Association [NATA], 2015). While clear protocols exist for administering nebulized albuterol in emergency situations, the optimal dosages for metered-dose inhalers are less clear. The AT should follow the patient’s asthma action plan provided by the prescribing physician (Hoffman et al, 2021)

ATs are not authorized to legally dispense prescription medication, but may be authorized to administer emergency medication, such as albuterol, under specific conditions as directed by the team physician. Standing orders should be established regarding AT use of bronchodilators such as inhalers and nebulizers, and these standing orders should be clearly documented and reviewed annually. It is important to recognize that laws change frequently, and all members of the sports medicine team must be aware of federal, state, and institutional regulations related to standing orders and the dispensing of both over-the-counter and prescription medications (Chang et al., 2018; Hoffman et al., 2021). The sports medicine team may include ATs, team physicians, physical therapists, and school nurses, so it is essential that each member remain in compliance with all current federal, state, and institutional regulations concerning medication management in a sports medicine setting (Chang et al., 2018; Hoffman et al., 2021).

Additionally, ATs should monitor environmental conditions, promote compliance with medication regimens, and educate athletes on self-management techniques and emergency response procedures. Collaboration with physicians and respiratory specialists is essential to optimize performance and safety.

Management of acute asthma exacerbations focuses on rapid reversal of airway obstruction, reduction of inflammation, and prevention of re-obstruction. Often, this can be caught early and managed in an outpatient setting with close follow-up. However, if the patient presents with a more severe exacerbation or fails to improve with current treatment interventions, emergency or critical care approaches must be used.

Patients may present with rapid, labored breathing, use of accessory muscles, nasal flaring, and difficulty speaking in full sentences due to breathlessness. Audible wheezing is often present, though in extreme cases, airflow may be so limited that breath sounds are diminished or absent (“silent chest”), which is a grave sign of impending respiratory failure. Oxygen saturation may drop below 92% on room air, and peak expiratory flow readings typically fall to less than 50% of predicted or personal best. Other warning signs include tachycardia, anxiety, fatigue, and agitation that can quickly progress to confusion or lethargy as hypoxemia worsens. Recognition of these clinical features is essential to differentiate a mild flare from one that necessitates emergency-level care.

Management approaches for severe exacerbations include frequent or continuous administration of SABAs such as albuterol, often delivered via nebulizer. In moderate to severe cases, ipratropium bromide, a short-acting muscarinic antagonist, may be added to enhance bronchodilation. Systemic corticosteroids can be given orally or IV, ideally within the first hour of presentation to the emergency department, to address the underlying inflammation and prevent symptom progression. If needed, supplemental oxygen should be provided to maintain oxygen saturation above 90-92%. Close monitoring of respiratory rate, oxygenation, and peak expiratory flow is critical, as deterioration can occur rapidly.

Further escalation of therapy may include magnesium sulfate IV for patients who do not respond to initial bronchodilator therapy, as it relaxes smooth muscle and provides additional bronchodilation. In cases of impending respiratory failure, evidenced by worsening hypoxemia, rising carbon dioxide, exhaustion, or altered mental status, advanced airway support may be necessary. Intubation is considered a last resort because mechanical ventilation in asthmatics can be technically challenging due to dynamic hyperinflation and risk of barotrauma. Non-invasive ventilation may be attempted in carefully selected patients but requires close monitoring.

A particularly severe complication is status asthmaticus, defined as a life-threatening asthma exacerbation that is refractory (unresponsive) to initial standard treatments, including repeated doses of SABAs and systemic steroids. Patients with status asthmaticus often present with severe dyspnea, inability to speak in full sentences, tachypnea, use of accessory muscles, and eventually fatigue, hypoxemia, or a silent chest. Management requires aggressive, continuous bronchodilator therapy, intravenous corticosteroids, possible IV magnesium sulfate, and, in some cases, adjunctive therapies such as ketamine for its bronchodilator properties. Patients require ICU-level care and continuous monitoring outside the scope of this course (Buttaro et al., 2025).

The Global Initiative for Asthma (GINA) is an international collaborative program launched in 1993 under the World Health Organization and the National Heart, Lung, and Blood Institute (Global Initiative for Asthma [GINA], 2024). Its purpose is to provide evidence-based, annually updated recommendations for the diagnosis, management, and prevention of asthma worldwide. Because asthma prevalence and healthcare resources vary significantly across regions, GINA’s guidance is designed to be adaptable to diverse clinical settings, from high-resource health systems to low- and middle-income countries. GINA’s strength lies in its frequent updates, global scope, and emphasis on both clinical and public health approaches to asthma management (GINA, 2024).

In the United States, asthma care has traditionally been guided by the National Asthma Education and Prevention Program (NAEPP) under the National Heart, Lung, and Blood Institute (NHLBI), with the most recent focused updates published in 2020 (NHLBI, 2021). While both GINA and NAEPP share the overarching goal of improving asthma outcomes, they differ in key areas. GINA has eliminated short-acting beta₂ agonist (SABA) monotherapy, recommending that all patients (even those with mild asthma) receive inhaled low-dose formoterol as needed. In contrast, NAEPP still permits SABA-only treatment for intermittent asthma, especially in children and adults with infrequent symptoms, and introduces ICS therapy only when asthma becomes persistent (GINA, 2024; NHLBI, 2021).

Additionally, GINA emphasizes a two-track approach: track 1 with formoterol preferred, track 2 with SABA + ICS as an alternative, while NAEPP maintains a more traditional stepwise ladder of increasing therapy. GINA also more explicitly integrates biomarkers (eosinophils, IgE) and biologics into its recommendations for severe asthma, while NAEPP references these therapies but with less prescriptive guidance.

These differences have important clinical implications. By discouraging SABA-only treatment, GINA directly addresses evidence that SABA monotherapy is linked to a higher risk of severe exacerbations and even asthma-related death. Following GINA’s approach may therefore reduce hospitalizations and improve long-term control, but it can also increase medication costs and raise issues of accessibility in resource-limited systems. In contrast, the NAEPP’s more conservative stance reflects a balance between efficacy, safety, and practical considerations within the U.S. healthcare system, where insurance coverage and prescribing patterns play major roles (GINA, 2024; NHLBI, 2021).

For clinicians, being aware of both sets of guidelines is important. GINA offers a more preventive and globally harmonized strategy, while NAEPP remains the standard reference for U.S.-based practice.

Scenario

Maria, a 22-year-old college student, presents to her primary care clinic with complaints of recurrent wheezing, chest tightness, and coughing that have worsened over the past two weeks. She reports waking up at night three times per week due to coughing and needing to use her albuterol inhaler almost daily. Maria has a history of asthma diagnosed in childhood, but has not been on a daily controller medication since high school. She lives in a dormitory where dust and mold are common, and she admits to skipping cleaning because of her busy schedule. Her physical exam reveals expiratory wheezes, oxygen saturation (SpO₂) of 94% on room air, and a peak flow measurement at 65% of her predicted personal best, which improves following bronchodilator administration.

Interventions

The provider initiates Step 3 therapy using a low-dose inhaled corticosteroid (ICS) and long-acting beta₂ agonist (LABA) combination inhaler (budesonide formoterol [Symbicort]), with instructions for both daily maintenance and as-needed use. Maria is educated on proper inhaler technique and provided a spacer to improve medication delivery. She is also instructed on the use of a peak flow meter to track her lung function at home, establishing her “personal best” baseline for comparison. Environmental control strategies are discussed, including frequent cleaning, use of dust-mite covers, and reducing mold exposure. Additionally, she is referred to the university’s asthma education program for ongoing support and provided with an individualized asthma action plan to guide her in adjusting therapy based on symptoms and peak flow readings.

Discussion

This case highlights the importance of reassessing asthma severity when symptoms worsen. Based on her frequency of nighttime awakenings, daily SABA use, and spirometry results, Maria’s asthma is best classified as moderate persistent, warranting escalation to Step 3 therapy. The combination of an ICS with a LABA not only targets acute bronchoconstriction but also addresses underlying airway inflammation, which is crucial for long-term control. Education was a key component of her care; without correct inhaler technique and trigger avoidance, medication alone may not achieve adequate control. The use of a peak flow meter adds an objective measure that empowers the patient to recognize early declines in lung function.

The case also demonstrates the real-world impact of social determinants of health. Maria’s dorm environment exposed her to common triggers like dust and mold, illustrating how living conditions can undermine asthma management. Her busy academic schedule contributed to neglecting cleaning and self-care, emphasizing the need for practical, patient-centered strategies. Addressing these contextual factors is as critical as prescribing medications.

Strengths

This case emphasizes a holistic approach to asthma management: pharmacological escalation consistent with guideline-based care, reinforcement of inhaler technique, nonpharmacological trigger reduction, and patient education. By including a peak flow meter and an asthma action plan, the intervention promotes self-management, which is strongly linked to reduced emergency visits and improved outcomes. The referral to an asthma education program also demonstrates strong interprofessional collaboration.

Weaknesses

One limitation in Maria’s management is the potential for adherence challenges. Young adults often struggle with consistent use of daily controller therapy, particularly when they feel better after initial improvement. Her living environment poses ongoing challenges that may be difficult to fully resolve without structural changes, such as moving to different housing. Additionally, while pharmacologic therapy was escalated appropriately, the provider may need to monitor closely for side effects or overreliance on as-needed LABA use. Finally, psychosocial factors such as stress and academic pressures were not directly addressed, though these may influence symptom control.

Scenario

Ethan, a 6-year-old boy, is brought to the pediatric clinic by his parents with a history of recurrent coughing and wheezing episodes over the past six months. The parents report that his cough is worse at night and is often triggered by playing outside or during viral URIs. They note two urgent care visits in the past year for “bronchitis,” where he was treated with antibiotics and short courses of oral steroids, with temporary improvement. His medical history is significant for eczema, and his mother has asthma. On today’s visit, Ethan is afebrile, with a respiratory rate of 24 breaths per minute, heart rate of 105, and oxygen saturation (SpO₂) of 95% on room air. On auscultation, bilateral expiratory wheezes are noted. A peak flow measurement is 70% of predicted for his age and height, and symptoms improve after albuterol via nebulizer.

Interventions

The pediatrician discusses the likelihood of asthma based on the pattern of recurrent, variable respiratory symptoms, family history of atopy, and Ethan’s positive response to bronchodilator therapy. A diagnosis of mild persistent asthma is made. Ethan is prescribed a low-dose inhaled corticosteroid (fluticasone [Flovent]) with a spacer to be used daily, along with an as-needed short-acting beta₂-agonist (albuterol [Ventolin]) for acute symptoms. His parents are educated on proper inhaler and spacer technique, and an asthma action plan is developed, including guidance for managing exacerbations and when to seek urgent care. Environmental control strategies are reviewed, including minimizing dust exposure, controlling pollen entry by keeping windows closed during allergy season, and avoiding exposure to secondhand smoke. Ethan’s parents are also instructed to monitor daily peak flow to track lung function variability.

Discussion

This case illustrates the process of diagnosing asthma in a young child, which is often challenging because symptoms can overlap with recurrent viral infections or bronchitis. Key features supporting the diagnosis include nighttime cough, symptom triggers (exercise, viral illness, allergens), recurrent episodes requiring systemic steroids, family history of asthma, and reversibility of airway obstruction with bronchodilators. Initiating a controller medication (ICS) is appropriate for mild persistent asthma, as daily anti-inflammatory therapy reduces symptom frequency, prevents exacerbations, and improves quality of life. Teaching parents correct inhaler technique and trigger management is equally important, as poor technique or ongoing environmental exposures can undermine treatment effectiveness.

Strengths

This case highlights early recognition of asthma and the importance of establishing control before the disease progresses to more severe forms. Strengths of the management include the use of guideline-based therapy with low-dose ICS, the provision of a personalized asthma action plan, and the education of parents to become active participants in care. Including peak flow monitoring empowers the family to detect early warning signs and reinforces self-management.

Weaknesses

Challenges in this case include the potential difficulty young children have in consistently using inhalers correctly, even with a spacer. Parental adherence to daily controller therapy may also be variable, especially if symptoms improve quickly, leading to underuse of ICS. Additionally, exposure to triggers in the home or school environment may not be fully controllable, limiting the impact of environmental interventions. Finally, objective testing such as spirometry is less reliable in young children, so diagnosis often relies on clinical patterns and treatment response, which can lead to uncertainty in early management.

Asthma remains a complex, multifactorial disease that requires careful assessment and a comprehensive management approach. By ensuring a deep understanding of the disease, clinicians can better tailor care to individual patients across the lifespan. Emphasis on stepwise management ensures care that reduces exacerbations and improves quality of life. Ultimately, integrating evidence-based recommendations with patient-centered care empowers healthcare professionals to address disparities, optimize outcomes, and meet the ongoing public health challenge posed by asthma.

• Anderson, S. D., & Kippelen, P. (2019). Exercise-induced bronchoconstriction: Pathogenesis. Current Allergy and Asthma Reports, 19(8), 44. Visit Source.
• American Lung Association (ALA). (2024). Measuring your peak flow rate. American Lung Association. Visit Source.
• Asthma and Allergy Foundation of America (AAFA). (2022). The allergic or atopic march. Asthma and Allergy Foundation of America. Visit Source.
• Asthma and Allergy Foundation of America (AAFA). (2024). Spirometry: A measure of airflow and volume (quick glance guide).  American Lung Association. Visit Source.
• Brashers, S., Huether, E., McCance, K.L., Valentina L. (2025). Understanding pathophysiology 8th ed. Elsevier. Visit Source.
• Burchum, L.D. and Rosenthal, J. R. (2025). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants, 3rd ed. Elsevier. Visit Source.
• Buttaro, T. M., Polgar-Bailey, P., Sandberg-Cook, J., Dick, K., & Montgomery, J. B. (2025). Primary care, 7th ed. Elsevier. Visit Source.
• Centers for Disease Control and Prevention (CDC). (2023). Asthma surveillance in the United States, 2001–2021. National Center for Environmental Health. Visit Source.
• Chang, C. J., Weston, T., Higgs, J. D., Ohkubo, M., Sauls, A., Tedeschi, F., White, M., & Young, C. C. (2018). Inter-Association Consensus Statement: The management of medications by the sports Medicine team. Journal of Athletic Training, 53(11), 1103–1112. Visit Source.
• Cockcroft, D.W., Davis, B.E. & Blais, C.M. (2020). Comparison of methacholine and mannitol challenges: Importance of method of methacholine inhalation. Allergy Asthma Clinical Immunology, 16, 14. Visit Source.
• Commission on Accreditation of Athletic Training Education (CAATE). (2020). Standards and procedures for accreditation of professional programs in athletic training. Commission on Accreditation of Athletic Training Education. Visit Source.
• Global Initiative for Asthma (GINA). (2020). Asthma Management and Prevention for adults and children older than 5 years. Global Initiative for Asthma. Visit Source.
• Global Initiative for Asthma (GINA). (2024). Summary guide for asthma management and prevention. For adults, adolescents and children 6-11 years. Global Initiative for Asthma. Visit Source.
• Hoffman, M., Murphy, M., Koester, M. C., Norcross, E. C., & Johnson, S. T. (2021). Use of lifesaving medications by athletic trainers. Journal of Athletic Training, 57(7), 613–620. Visit Source.
• Kavanagh, J., Jackson, D. J., & Kent, B. D. (2019). Over- and under-diagnosis in asthma. Breathe, 15(1), e20–e27. Visit Source.
• Kuruvilla, M. E., Lee, F. E., & Lee, G. B. (2019). Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clinical Reviews in Allergy & Immunology, 56(2), 219–233. Visit Source.
• Martin, J., Townshend, J., & Brodlie, M. (2022). Diagnosis and management of asthma in children. BMJ Paediatrics Open, 6(1), e001277. Visit Source.
• Merck Manual Professional Version. (2025). Table: Classification of asthma severity. Merck Manual Professional Version. Visit Source.
• Morris, M. J. (2020). Exercise-induced bronchoconstriction: Diagnosis and management. American Family Physician, 101(9), 541–548.
• Morris, M.J. (2024). Asthma differential diagnoses. Medscape. Visit Source.
• National Athletic Trainers’ Association. (2015). Position statement: Management of asthma in athletes. Journal of Athletic Training, 50(8), 777–793. Visit Source.
• National Heart, Lung, and Blood Institute [NHLBI]. (2021). Asthma management guidelines: Focus updates 2020. U.S. Department of Health and Human Services, National Institutes of Health. Visit Source.
• National Heart, Lung, and Blood Institute [NHLBI]. (2024). Asthma: Causes and triggers. U.S. Department of Health and Human Services. Visit Source.
• Ora, J., De Marco, P., Gabriele, M., Cazzola, M., & Rogliani, P. (2024). Exercise-Induced Asthma: Managing Respiratory Issues in Athletes. Journal of functional morphology and kinesiology, 9(1), 15. Visit Source.
• Pate, C. A., & Zahran, H. S. (2024). The Status of Asthma in the United States. Preventing Chronic Disease, 21, E53. Visit Source. https://doi.org/10.5888/pcd21.240005Sen, P., Khatri, S. B., & Tejwani, V. (2023). Measuring exhaled nitric oxide when diagnosing and managing asthma. Cleveland Clinic Journal of Medicine, 90(6), 363–370. Visit Source.
• Sharma, G. D. (2024). Pediatric asthma differential diagnoses. Medscape. Visit Source.
• Upmc. (2021). EILO vs Exercise-Induced Asthma: What’s the Difference? UPMC HealthBeat. Visit Source.
• U.S. Anti-Doping Agency. (2025). What Athletes Need to Know about Inhaled Medications.  USADA. NPC Hello. Visit Source.
• van Dijk, B. C. P., Svedsater, H., Heddini, A., Nelsen, L., Balradj, J. S., & Alleman, C. (2020). Relationship between the Asthma Control Test (ACT) and other outcomes: A targeted literature review. BMC Pulmonary Medicine, 20(1), 79. Visit Source.
• Weiler, J. M., Brannan, J. D., Randolph, C., Hallstrand, T. S., Parsons, J. P., Silvers, W., Storms, W. W., & Zeiger, J. S. (2016). Exercise-induced bronchoconstriction update—2016. Journal of Allergy and Clinical Immunology, 138(5), 1292–1295.e36. Visit Source.
• World Health Organization (WHO). (2024). Asthma. World Health Organization. Visit Source.
• World Anti-Doping Agency (WADA). 2026. TUE Physician Guidelines Asthma Version 9.2. World Anti-Doping Agency. Visit Source.